The positive results from the Phase 1b/2 study indicate that the combination of uliledlimab and toripalimab has a favorable safety profile and shows efficacy in treating advanced non-small cell lung cancer. This news may increase investor confidence in I-Mab's ability to develop effective treatments, potentially leading to a short-term increase in the stock price.